A

Acticor Biotech SA
PAR:ALACT

Watchlist Manager
Acticor Biotech SA
PAR:ALACT
Watchlist
Price: 0.25 EUR
Market Cap: 3.9m EUR

Relative Value

There is not enough data to reliably calculate the relative value of ALACT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALACT Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
0.1
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-3.5
Industry
24
Forward
0.1
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-5
Industry
21.6
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-5.7
Industry
23.7
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.7
Industry
3.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
0.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-4
Industry
6.7
Forward
0.1
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-3.8
Industry
7.2
Forward
0.1
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-4.6
Industry
8.2
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-4.6
Industry
6.7
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
18
Industry
5.7

Multiples Across Competitors

ALACT Competitors Multiples
Acticor Biotech SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Acticor Biotech SA
PAR:ALACT
3.9m EUR 0 -0.2 -0.2 -0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
394.1B USD 6.6 167.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
168.9B USD 4.7 24.1 17.5 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
148.2B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111B USD 9.5 30.2 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.9B USD 5.1 15.9 15.1 17.1
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.8 19.5 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.7B USD 17 1 256.1 165.2 200.4
NL
argenx SE
XBRU:ARGX
46.9B EUR 15.1 35.6 61.5 63.2
P/S Multiple
Revenue Growth P/S to Growth
FR
A
Acticor Biotech SA
PAR:ALACT
Average P/S: 3 411 359.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 111 463.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
0.9
US
E
Epizyme Inc
F:EPE
2 065.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17
46%
0.4
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
P/E Multiple
Earnings Growth PEG
FR
A
Acticor Biotech SA
PAR:ALACT
Average P/E: 195.9
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 256.1
N/A N/A
NL
argenx SE
XBRU:ARGX
35.6
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
A
Acticor Biotech SA
PAR:ALACT
Average EV/EBITDA: 40.4
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.5
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.2
N/A N/A
NL
argenx SE
XBRU:ARGX
61.5
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
A
Acticor Biotech SA
PAR:ALACT
Average EV/EBIT: 46.6
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.5
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
200.4
N/A N/A
NL
argenx SE
XBRU:ARGX
63.2
N/A N/A